What We're Reading: Page
Industry reads hand-picked by our editors
Sep 01, 2021
Aug 31, 2021
-
POLITICO
CDC vaccine panel: Let regulators lead on Covid-19 booster shots
-
MedPage Today
Mineral Oil Likely Accounts for Some - But Not All - of Vascepa's ASCVD Benefit
-
MIT Technology Review
Can you spot the fake receptor? The coronavirus can't either.
-
BioSpace
Startup Runs with Old Novartis Muscle Loss Drug to Fight Obesity
Aug 30, 2021
-
Reuters
Biogen offers free Alzheimer's drug as Medicare payment uncertainty remains
-
Financial Times
Pfizer ramps up its salesforce in battle of vaccine boosters
-
STAT
Four ways Elizabeth Holmes could win over a jury
-
The Wall Street Journal
Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion
Aug 27, 2021
-
The Wall Street Journal
Elizabeth Holmes’s Trial Could Reveal Her Side of Theranos Story
-
Science
Having SARS-CoV-2 once confers much greater immunity than a vaccine—but no infection parties, please
-
Evaluate Vantage
ESC 2021 – Jardiance blows Entresto out of the water
-
Reuters
U.S. judge declines to stop J&J from splitting talc liabilities from main business
Aug 26, 2021
-
The Wall Street Journal
Biden Administration Likely to Approve Covid-19 Boosters at Six Months Instead of Eight
-
Bloomberg
Cassava Plunges After Alzheimer’s Data Draws Scrutiny, Shorts
-
Science
New WHO group aims to improve efforts to find pathogen origins
-
Bloomberg
Advent Said to Weigh Purchase of Swedish Biotech Firm Sobi
Aug 25, 2021
-
MIT Technology Review
Is Ginkgo’s synthetic-biology story worth $15 billion?
-
The Atlantic
The FDA Really Did Have to Take This Long
-
The Boston Globe
Moderna is now the third largest biotech employer based in Mass.
-
Endpoints News
Roche tees up $3B+ for Shape's RNA editing platform, with the bold promise of 'one-time' cures for Alzheimer's, Parkinson's
Aug 24, 2021
-
STAT
Flagship, Orbimed, ARCH top list of high-performing biotech VC firms
-
Bloomberg
Small-Cap Biotech Stocks Play Catch Up With Industry Leaders
-
Endpoints News
PDUFA VII: What's new, and what's significant in the next user fee deal
-
Fierce Biotech
Merck KGaA's $4.2B bintrafusp alfa nabs a 3rd strike. Is the GSK-partnered cancer hopeful out?
Previous
